about
Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern ChinaFirst-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemotherapy in NSCLC: historical review.
@ast
Chemotherapy in NSCLC: historical review.
@en
type
label
Chemotherapy in NSCLC: historical review.
@ast
Chemotherapy in NSCLC: historical review.
@en
prefLabel
Chemotherapy in NSCLC: historical review.
@ast
Chemotherapy in NSCLC: historical review.
@en
P1433
P1476
Chemotherapy in NSCLC: historical review.
@en
P2093
Paris Kosmidis
P304
P356
10.1016/S0169-5002(02)00261-1
P478
38 Suppl 3
P577
2002-12-01T00:00:00Z